PHE2 Antibody

Definition and Biological Significance of PGE2 Antibodies

PGE2 antibodies are immunoglobulins designed to specifically recognize and bind prostaglandin E2, a downstream metabolite of arachidonic acid produced by cyclooxygenase (COX) enzymes. These antibodies enable:

• Quantitative detection of PGE2 in biological samples

• Functional neutralization of PGE2 in experimental and therapeutic contexts

• Investigation of PGE2-mediated signaling pathways in inflammation, cancer, and immune regulation

2.1. Antibody Structure

PGE2 antibodies exhibit canonical IgG architecture, comprising:

• Fab regions: Contain hypervariable loops (CDRs) critical for PGE2 binding

  • Example: Anti-PGE2 mAb 2B5 uses a 17-residue CDRH3 for high-affinity interaction (Kd ≈ 300 pM)

• Hinge region: Enables Fab flexibility for optimal antigen engagement

• Fc region: Mediates immune effector functions (e.g., phagocytosis)

2.2. Epitope Specificity

3.1. Neutralization of PGE2 Signaling

• In vitro: Blocks PGE2 binding to EP2/EP4 receptors (IC50 <10 nM)

  • Suppresses T cell anergy in tumor microenvironments

• In vivo: Reduces nociception in murine models (ED50 ≈ 1 µg/kg)

3.2. Immunoassay Applications

• Radioimmunoassays detect PGE2 at 0.1–10 ng/mL sensitivity

• Competitive binding assays show linearity between 0.75–4.2 nM

4.1. Cancer Immunotherapy

• PGE2 antibodies restore IL-2 responsiveness in CD8+ TILs by:

  • Upregulating IL-2Rγc expression (2.1-fold increase)

  • Enhancing STAT5 phosphorylation (p <0.01 vs. controls)

• Combination with checkpoint inhibitors improves tumor regression rates in syngeneic models

4.2. Inflammatory Disease Models

5.1. Specificity Issues

• Polyclonal antibodies show significant cross-reactivity with structurally similar prostaglandins (e.g., PGE1, PGA2)

• Batch-to-batch variability remains problematic for polyclonal preparations

5.2. Stability Considerations

• Lyophilized monoclonal antibodies retain activity for >24 months at -80°C

• Repeated freeze-thaw cycles reduce binding capacity by 18–22% per cycle

Future Directions

• Engineering bispecific antibodies targeting PGE2 and PD-1/CTLA-4

• Development of camelid nanobodies for intratumoral delivery

• CRISPR-based screening to identify PGE2-high tumor subtypes for antibody targeting